Effect of Venous Cannulation on the Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass
Effect of Venous Cannulation on the Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass
Context Atrial fibrillation is the most frequent arrhythmia following coronary artery bypass
 grafting. POAF is associated with worse outcomes following CABG. In addition, recurrence of
 AF is associated with longer hospital stay and higher rate of neurological and renal
 complications compared to a single episode of AF Objective To estimate the proportion of
 eligible people who are willing to participate, number of participants who drop out of the
 trial and use the results of this study to inform a larger study.

 Study Design:

 Pilot randomized controlled trial. Patients will be blinded to the intervention.

 Participants:

 The study population will include 40 patients. Patients admitted to the Jewish General
 Hospital for elective coronary artery bypass grafting from May 2021 will be included in the
 study. Patients will be included if they were in sinus rhythm with a HR ≥50 bpm, undergoing
 on-pump coronary artery bypass grafting and hemodynamically stable. Patients will be excluded
 from the study if they meet any of the following criteria: Second or third degree heart
 block, LVEF <35%, left atrial volume index ≥42 ml/m2, right atrial volume index > 47 ml/m2,
 any degree of tricuspid regurgitation, any degree of right ventricular dysfunction, emergency
 or minimally invasive operation, concurrent valve operation, history of atrial fibrillation
 or previous cardiac surgery

 Study Interventions and Measures Patients will be randomly assigned to one of two treatment
 groups according to the venous cannulation technique used during surgery. Group A will
 undergo cavoatrial cannulation with a 2-stage venous cannula. Group B will undergo bicaval
 cannulation with snares. Similar surgical methods will be used in all treatment groups .

 The primary endpoint will be defined as any episode of atrial fibrillation in any participant
 lasting >5 minutes in duration or any episode leading to hemodynamic compromise (SBP<90 mmHg)
 or causing symptoms (angina or dyspnea). Atrial fibrillation will be diagnosed using
 telemetry and a 12-lead ECG. Patients will be followed up in 1 month with a 12-lead ECG to
 determine their rhythm. The secondary endpoints are the development of RV dysfunction,
 tricuspid regurgitation and any increase in left atrial volume index as detected by
 post-operative transthoracic echocardiography.
.Introduction

 Atrial fibrillation is the most frequent arrhythmia following coronary artery bypass
 grafting. Its incidence following cardiac surgery is estimated to be between ~10-60%1-5 . The
 incidence is lower in patients undergoing isolated coronary artery bypass grafting (~25-30%)
 compared to valve operations 2,6,7. It most commonly occurs in the first four days following
 cardiac surgery1,5,8. Despite many efforts to predict and prevent postoperative AF, the
 incidence has not changed over the past decades1-5,9 .

 Although in the past it was thought of as a benign self-limiting complication9, atrial
 fibrillation after cardiac surgery has been shown to be associated with worse outcomes
 compared to patients who remain in sinus rhythm postoperatively. It leads to increased length
 of hospital and ICU stay, higher rate of stroke, wound infection, renal failure, myocardial
 infarction and has a significant effect on early and long-term mortality2-4. In addition,
 recurrence of AF is associated with longer hospital stay and higher rate of neurological and
 renal complications compared to a single episode of AF 5.

 1.2Mechanisms of POAF

 Several studies have investigated the underlying mechanisms involved in development of
 post-operative atrial fibrillation. However, these mechanisms remain largely unclear. It is
 believed that atrial fibrillation is caused by reentry of multiple wavelets of excitation in
 the presence altered atrial refractoriness. This makes ectopic beats originating from foci in
 the pulmonary veins more likely to trigger an episode of atrial fibrillation 10-12.

 In their comprehensive review, Maesen B et al illustrate the various factors that lead to the
 development of atrial fibrillation. It is triggered by an interaction of acute factors of
 surgery and pre-existing factors chronic in the patient 1. In other words, factors related to
 cardiac surgery such as inflammation, oxidative stress and sympathetic activation, together
 with the presence of an atrial substrate, predispose to the development of POAF 1,12. The
 most common co-morbid conditions the increase the susceptibility of AF are hypertension,
 heart failure, mitral valve disease and coronary artery disease12. These co-morbidities also
 lead to atrial dilation, which is a key factor in the development of an atrial substrate12.

 To support this hypothesis, Maesen B et al explain that drugs, which increase sympathetic
 activity in the heart such as milrinone, dobutamine and dopamine, increase the incidence of
 POAF. They also demonstrate that perioperative beta-blockers reduced POAF incidence. This is
 supported a meta-analysis of 33 randomized controlled trials investigating beta-blocker
 treatment for prevention of POAF. Perioperative beta-blockers led to a reduction in the
 incidence of postoperative AF13 .

 Maesen B et al also argue that inflammation and oxidative stress -caused by surgical trauma
 and use of cardiopulmonary bypass- contribute to the development of POAF by demonstrating
 that treatment with ascorbic acid or N-acetyl cysteine, both antioxidants, reduced the
 incidence of POAF1.

 In addition, drugs with anti-inflammatory properties such as corticosteroids and statins have
 -in many studies- reduced the incidence of POAF1. This is also supported by various studies
 that found an association between AF and high levels of inflammatory markers such as
 C-reactive protein and Interleukin-614.

 1.3Risk factors for POAF

 Several studies have investigated the risk factors that could lead to the development of
 postoperative AF and attempted to provide a risk stratification model5,15-17. These attempts
 were unsuccessful in establishing a comprehensive predictive model for POAF.

 The most consistent preoperative risk factor for POAF in those studies is older age 5,15-17.
 Age has been shown to be most strongly associated with development of POAF. The studies
 frequently mention the following as pre-operative factors: prior history of AF, congestive
 heart failure, COPD, diabetes mellitus, left ventricular hypertrophy and left atrial
 enlargement.

 In their prospective study of patients undergoing cardiac surgery, Chu et al found that a
 CHADS-VASc score of more than 2 (Congestive heart failure, Hypertension [blood pressure
 >140/90 mmHg or treated hypertension on medication], Age >75years, diabetes mellitus, prior
 Stroke or transient ischemic attack or thromboembolism, vascular disease, Age 65 to 74 years,
 Sex category [female gender]) was associated with increased incidence of POAF 17.

 Perrier et al confirmed these findings in their cohort study of 1481 patients who underwent
 isolated CABG8. Additionally, they have found that obesity, renal failure, preoperative
 beta-blockers and preoperative antiplatelet therapy to be independent risk factors for POAF
 8. This is in contrast to most studies, which found that preoperative beta-blockers decreased
 the incidence of POAF.

 In a study by Avi et al, pre-operative right ventricular dysfunction as measured by RV
 myocardial performance index (MPI) -which is a measurement of RV systolic and diastolic
 function- was demonstrated to be a predictor of POAF in patients undergoing isolated CABG6.

 With regards to postoperative factors, a multicenter observational study found that
 postoperative withdrawal of beta-blockers or ACE inhibitors correlate with increased
 incidence of POAF 5.

 The role of potassium and magnesium supplementation to treat hypokalemia and hypomagnesaemia
 in order to prevent ventricular arrhythmias after myocardial infarction is well recognized.
 In addition, low serum magnesium has been shown to be associated with increased incidence of
 atrial fibrillation in the general population18. However, low serum magnesium hasn't been
 well established as a predictor of POAF 19,20. The findings of studies on the beneficial
 effects of prophylactic administration of magnesium to prevent atrial fibrillation post
 cardiac surgery have been conflicting.13,21-23 A meta-analysis of 35 RCTs by Fairly et al
 found that magnesium supplementation reduced the risk of atrial fibrillation
 postoperatively21. However, their analysis was limited by significant heterogeneity between
 the studies. While another meta-analysis failed to show a prophylactic effect of magnesium or
 potassium supplementation against PAOF22 . Cook et al performed a meta-analysis of 5 RCTs
 after excluding the trials with methodological problems; they failed to show a prophylactic
 effect of magnesium against AF23.

 Furthermore, Kalus et al and Matsuura et al investigated the impact of volume overload on the
 incidence of AF, they found that increased fluid balance on the first or second postoperative
 days after cardiac surgery was an independent predictor of POAF 24,25. Both studies
 hypothesized that volume overload will lead to left atrial dilation and thus predispose to
 AF. However, neither of the studies had recorded measurements of left atrial size.

 Few studies have investigated the intraoperative factors of POAF. It is known that concurrent
 valve surgery increases the risk of POAF5,17. Other risk factors found consistently in the
 literature include cardiopulmonary bypass and aortic cross clamp times10,15,16,26. A
 multicenter study found that bicaval cannulation and pulmonary vein venting might be
 associated with increased risk of POAF 5. In addition, an earlier retrospective study found
 that snared bicaval cannulation was associated with increased incidence of postoperative
 atrial arrhythmias in patients receiving high volume crystalloid cardioplegia. However this
 effect was not observed when low volume cardioplegia was used to compare unsnared bicaval
 cannulation with cavoatrial cannulation9.

 It has been postulated that atrial incision and atrial ischemia during surgery lead to
 alterations of atrial conduction and refractoriness thereby predisposing to the development
 of POAF 10. In addition, Tchervenkov et al found an association between persistence of
 residual atrial electrical activity during cardioplegic arrest and post-operative atrial
 tachyarrhythmia27. It might be that atrial activity during cardioplegic arrest -which could
 be due to inadequate atrial protection - resulted in atrial ischemia, which in turn
 contributes to POAF development 27. It has been demonstrated that return of relatively warm
 venous blood to the right atrium and ventricle may lead to myocardial warming thereby
 diminishing the protective effect of cardioplegia. Older animal studies have shown
 conflicting results regarding the optimal cannulation technique to reduce myocardial
 rewarming during arrest28,29. Furthermore, no study prospectively investigated the effect of
 different cannulation techniques on post-operative atrial tachyarrhythmia.

 Due to the scarcity of data regarding the intraoperative risk factors of POAF, these factors
 are not well recognized and preventative strategies are therefore not well established.

 2 Objectives To estimate the proportion of eligible people who are willing to participate,
 the number of participants who drop out of the trial and use the results of this study to
 inform a larger study.

 3. Study design 3.1 Recruitment and sample size Participants will be screened to enter the
 study in clinic by the principal investigator who is cardiac surgeon. Only the principal
 investigator's patients who meet inclusion criteria will be considered in the study.
 Eligibility to enter the study will be determined during the patient's consultation in
 clinic.

 Considering we usually operate on 1 or 2 patients per week who meet inclusion criteria. We
 believe that 20 patients per group is reasonable to assess feasibility of recruitment and
 protocol implementation.

 3.2 Study population and study procedure

 Patients admitted to the Jewish General Hospital for elective coronary artery bypass grafting
 from January 2021 will be included in the study. Patients will be screened in clinic prior to
 admission. The study population will include 40 patients that will be randomly assigned to
 one of two treatment groups according to the venous cannulation technique used during
 surgery. Group A will undergo cavoatrial cannulation with a 2-stage venous cannula. Group B
 will undergo bicaval cannulation with snares.

 3.3 Intervention Bicaval cannulation will be performed through in the right atrium. Small
 tapes are passed around the SVC and IVC. Two purse string sutures are placed in the superior
 and inferior portions of right atrium. Two small incisions are made inside the purse string
 sutures. The SVC and IVC are cannulated through the superior and inferior incisions
 respectively. The purse string sutures and small tapes passed through small tubes and snared.
 The small tapes snare will act as a tourniquet to prevent venous return to the right atrium.
 Bicaval cannulation is performed in cases of mitral and tricuspid valve operations to provide
 a bloodless operative field, superior drainage of venous blood and potentially better
 protection of the heart compared to cavoatrial cannulation. Similar surgical methods will be
 used in all treatment groups. We will use a standard sternotomy incision to access the heart,
 the distal ascending aorta be will cannulated. Antegrade Del Nido cardioplegia will be used
 to arrest the heart under normothermia. The left internal mammary artery will be grafted to
 the left anterior descending artery. For the other grafts, the left radial artery and
 saphenous venous grafts will be used where appropriate. The saphenous vein will be harvested
 endoscopically and the radial artery will be harvested using an open technique. Pre-operative
 beta-blockers will be continued to the day of surgery and re-started on the first
 post-operative day if heart rate and blood pressure were permissible.

 3.4 Randomization and blinding Patients will be screened in clinic. They will be blinded to
 their treatment and will be prospectively randomized on hospital admission by simple
 randomization using a random numbers table. Randomization will be performed by the principal
 investigator.

 3.5 Study measurements Patients' data, including demographics, number of diseased coronary
 arteries and comorbidities such as presence of hypertension, chronic kidney disease, diabetes
 mellitus, peripheral vascular disease, previous stroke or myocardial infarction will be
 collected. Operative data including patients' temperature, cardiopulmonary bypass time,
 cross-clamp time, aortic and venous cannulation technique, number and location of bypasses
 will also be collected. Echocardiographic parameters will be collected preoperatively,
 intra-operatively and post-operatively. These will include left ventricular ejection
 fraction, right ventricular function, left and right atrial volume indices, RV myocardial
 performance index (MPI) and the presence of valvular heart disease. Postoperative data will
 include serum electrolytes, cardiac biomarkers, volume status and beta-blocker use.
 Postoperative echocardiogram will be done between POD 3-5 and while the heart is in sinus
 rhythm and with a heart rate <100bpm whenever possible.

 3.8 Data reporting Baseline and demographic data will be summarized by standard descriptive
 summaries e.g. means and standard deviations for continuous variables and percentages for
 categorical variables. Hypothesis testing will not be performed as this is a feasibility
 study and the sample size to too small to yield significant conclusions.

 4. Confidentiality Informed consent will be taken in clinic by the principal investigator
 during participant's visit. Participants will be informed that they're able to withdraw from
 the study at anytime pre-operatively. An additional consent form separate from the regular
 operation consent form will be used for the study.

 Data will be collected in a paper data collection form which will then be transferred to a
 secure excel document. The excel document will be password protected. Paper forms will be
 placed in a secure cabinet in a locked office. Only members of the research team will have
 access to the electronic and paper forms.

 5. Risk Assessment The risks associated with bicaval cannulation are minimal. There is
 potential for increased risk of bleeding because of the need for two incisions instead of
 one. Since we're cannulating the SVC and IVC indirectly through atrial incisions these
 potential bleeding sites can be easily seen and controlled intra-operatively.

 There is a possibility of increased incidence of atrial fibrillation post-operatively in the
 intervention group. Although uncommon, some surgeons routinely perform bicaval cannulation
 for CABG.

 Participants may benefit from the intervention if it leads to decreased rate of POAF. Thus
 avoiding the potential sequelae of AF and the side effects of treatment.

 6. PUBLICATION We plan to use the data obtained in this study for publication in a
 peer-review journal. We may present the findings of the study in scientific conferences. No
 identifiable information will be published.

 Appendix A: Consent form

 Study Title: Effect of venous cannulation technique on the incidence of post-operative atrial
 fibrillation in patients undergoing elective coronary artery bypass grafting. A pilot
 randomized controlled trial.

 Principle investigators: Jean-Francois Morin MD, Husain Esmaeil MD , Alex Alojko Study Site:
 Jewish General Hospital Address: 3755 Chemin de la Côte-Sainte-Catherine, Montréal, QC H3T
 1E2 Telephone: (514) 340-8222

 Introduction You are being asked to participate in a research study. Before agreeing to
 participate, it is important that you read the following explanation of this study.

 The decision to participate in this study is up to you. Your participation is completely
 voluntary. Your decision will not affect your relationship with your regular doctor or your
 current or future medical care.

 Please read this form carefully. Feel free to discuss the study with your family, friends,
 and healthcare provider before you make your decision whether to participate. Ask about
 anything you don't understand or would like explained better. Take time to decide whether or
 not you want to take part in this study and ask the study doctor or study staff as many
 questions about the study as you would like.

 Background and purpose You are being asked to take part in this study because you have been
 diagnosed with coronary artery disease and will undergo coronary artery bypass grafting.

 Atrial fibrillation is a type of heart arrhythmia that occurs in about 30% of patients
 undergoing coronary artery bypass grafting. This rhythm problem could cause a clot to form in
 the heart; this clot can travel to brain and cause a stroke. Atrial fibrillation is a
 treatable condition. The treatment method depends on the clinical situation. It is usually
 treated with medications that either controls the speed or the rhythm of the heart. If the
 arrhythmia causes severe symptoms such as chest pain, dizziness or hypotension (low blood
 pressure) it is sometimes treated with an electrical current (called electrical
 cardioversion) to restore the heart to its normal rhythm.

 During heart surgery, the heart will be stopped in order to perform the coronary artery
 bypass surgery. The heart will be connected to a heart-lung machine (also called
 cardiopulmonary bypass machine). This machine takes over the job of the heart and lungs. A
 plastic tube will be connected to right upper chamber of the heart (called the right atrium)
 to the machine (this tube is called the venous cannula); the tube carries blood from the
 heart into an oxygenator where it will be oxygenated. The oxygenated blood is pumped into the
 body through a tube connected to the aorta (the body's main blood vessel).

 Another method of the venous cannulation is by connecting two tubes to the superior vena cava
 and inferior vena cava (the two major veins carrying blood returning from the body to the
 right atrium of the heart). This is the same method used for mitral and tricuspid valve
 operations.

 The purpose of this study is to look into the effect of different venous cannulation methods
 on the occurrence of atrial fibrillation (a type of arrhythmia) post coronary artery bypass
 grafting. This study has 2 groups. You will be randomly assigned to one of the two groups.
 The first group will have the venous cannula connected to the right atrium (which is the
 standard method). The second group will have the venous cannula connected to the superior and
 inferior vena cava and a tie is secured around the cannula so that no blood passes into the
 right atrium instead, the blood goes to the heart-lung machine.

 Potential Risks

 There are potential risks to you by taking part in this study. The rate of occurrence of
 atrial fibrillation (heart arrhythmia) could be higher in the treatment group you are
 assigned to. The bleeding risk is theoretically higher since we are making an incision in 2
 areas to insert the cannulas instead of a single incision in the standard method. If bleeding
 occurs, you might need a blood transfusion or in uncommonly, you might need to be re-operated
 on to control the bleeding. In addition, there are some risks inherent to the coronary artery
 bypass grafting surgery, which include bleeding, heart attack, heart rhythm problems, heart
 failure (which is inadequate pumping of blood by the heart). Depending on the cause of the
 heart attack, It can be managed with medications, going back to surgery or by coronary
 angioplasty and placing a stent. Heart failure is treated with medications.

 Other potential risks of coronary artery bypass grafting include liver problems (elevated
 liver enzymes due to inadequate blood supply during the operation), kidney injury (due to
 inadequate blood supply during the operation). Liver and kidney complications are usually
 managed with monitoring of their functions.

 Other risks inherent to the surgery include lung problems such as lung infection, fluid
 collecting in the lungs or inability to disconnect the ventilator machine after the operation
 due to inability of the lungs to oxygenate the blood on their own and other uncommon risks
 such as stroke and death.

 Potential Benefits

 You may benefit as a result of your participation in this study. The rate of atrial
 fibrillation could be lower in the treatment group you are assigned to. However, there is no
 assurance that you will benefit from your participation in this study. Results from this
 study may benefit other patients in the future.

 Alternative Treatments

 This clinical study is for research purposes only. You do not have to participate in the
 study to receive treatment for coronary artery disease. The other option is a standard venous
 cannulation method in which the right atrium is cannulated.

 Voluntary Participation/Withdrawal Your decision to participate in this clinical research
 study is voluntary. You may choose not to participate or you may withdraw from the study for
 any reason at any time without penalty. You should tell the study doctor or study team if you
 decide to leave the study.

 The study doctor can stop the study or your participation in the study at any time without
 your consent if it appears to be medically harmful to you, if the study is cancelled, or for
 administrative reasons.

 Confidentiality As part of this research, we will collect personal information from you (this
 means information that can identify you). In order to protect your privacy, all information
 collected will remain confidential to the extent permitted by law. Your identifiable health
 information is protected by a law. If the results of this study are published or presented at
 meetings, you will not be identified.

 For monitoring, control, protection and security purposes, your research study file could be
 checked by persons authorized by the Research Ethics Committee of the CIUSSS du
 Centre-Ouest-de-l'Île de Montréal. These persons are bound by a confidentiality agreement.

 For all questions concerning your rights during your participation in this study, or if you
 have any complaints or comments regarding your experience in taking part in this research
 study, you can contact the Local Commissioner of Complaints and Quality of Service of the
 CIUSSS Centre-Ouest-de-l'Île-de-Montréal or the ombudsman of the institution at (514)
 340-8222, ex. 24222.

 STATEMENT OF CONSENT

 Study title: Effect of venous cannulation technique on the incidence of post-operative atrial
 fibrillation in patients undergoing elective coronary artery bypass grafting. A pilot
 randomized controlled trial.

 PARTICIPANT STATEMENT

 I understand the information that was explained to me as contained in this consent form. All
 my questions were answered to my satisfaction. I will receive a copy of this signed consent
 form. My participation is voluntary and I can withdraw from the research study at any time
 without any consequences and without having to give a reason. Withdrawing from this research
 study, at any time, will not affect my medical care now, or later, in any way. By signing
 this consent form, I do not give up any of my legal rights.

 I agree to participate in this research study.

 Name of Participant

 Signature Date

 RESEARCHER STATEMENT

 I, as the person obtaining consent, certify that I have explained to the participant or
 his/her legal representative (where applicable) the research study information contained in
 this consent form and have answered all questions. I have clearly explained to the
 participant that s/he is free to withdraw at any time without providing a reason, and without
 any consequences. I commit, together with the members of the research team to respect all
 conditions described in this consent form and to give a signed copy of the consent form to
 the participant.

 Name and signature of the researcher or person delegated to obtained consent

 Date

 Translator/Witness (if applicable)

 Name and signature of translator/witness Date
Inclusion Criteria:

 Patients admitted for coronary artery bypass grafting under the care of the principal
 investigator at the Jewish General Hospital during the study period will be included if
 they meet all the following criteria:

 1. Age >18 years

 2. Sinus rhythm with HR >50bpm

 3. Scheduled to undergo isolated elective on-pump CABG

 4. Hemodynamically stable.

 Exclusion Criteria:

 Patients will be excluded from the study if they meet any of the following criteria:

 1. Second or third degree heart block

 2. LVEF <35%

 3. left atrial volume index ≥42 ml/m2

 4. right atrial volume index > 47 ml/m2

 5. any degree of tricuspid regurgitation

 6. any degree of right ventricular dysfunction

 7. emergency or minimally invasive operation

 8. concurrent valve operation

 9. history of atrial fibrillation

 10. previous cardiac surgery

 11. previous catheter ablation for atrial fibrillation

 12. pre-operative use of class I or III anti-arrhythmics.